CAR-T CD19 / Sheba Medical Center - LARVOL DELTA

Outcomes of Salvage Therapy After Early-Line CD19 CAR-T Failure in Large B-Cell Lymphoma. (PubMed, Transplant Cell Ther) - "Post-CAR-T salvage therapy consisted of heterogeneous regimens, most commonly polatuzumab-bendamustine-rituximab and CD20 × CD3 bispecific antibody monotherapy. Response rates and short-term survival varied across approaches, with bispecific antibody monotherapy having the highest ORR (65%) and favorable 1-year outcomes (OS 56%; EFS 43%). In this contemporary multicenter cohort, salvage therapy after CAR-T failure achieved objective but often short-lived responses, with outcomes driven by relapse timing after CAR-T infusion rather than the line of prior CAR-T therapy, supporting individualized treatment selection in this high-risk setting."

Journal • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression (clinicaltrials.gov) - P2/3 | N=10 | Recruiting | Sponsor: Sheba Medical Center | Trial completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression (clinicaltrials.gov) - P2/3; N=10; Recruiting; Sponsor: Sheba Medical Center; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • IO Biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression (clinicaltrials.gov) - P2/3; N=10; Not yet recruiting; Sponsor: Sheba Medical Center

Clinical • IO Biomarker • New P2/3 trial